Implications of Phytoestrogen Intake for Breast Cancer

Christine Duffy, MD; Kimberly Perez, MD; Ann Partridge, MD, MPH

ABSTRACT Phytoestrogens are a group of plant-derived substances that are structurally or functionally similar to estradiol. Interest in phytoestrogens has been fueled by epidemiologic data that suggest a decreased risk of breast cancer in women from countries with high phytoestrogen consumption. Women with a history of breast cancer may seek out these “natural” hormones in the belief that they are safe or perhaps even protective against recurrence. Interpretation of research studies regarding phytoestrogen intake and breast cancer risk is hampered by differences in dietary measurement, lack of standardization of supplemental sources, differences in metabolism amongst individuals, and the retrospective nature of much of the research in this area. Data regarding the role of phytoestrogens in breast cancer prevention is conflicting, but suggest early exposure in childhood or early adolescence may be protective. In several placebo-controlled randomized trials among breast cancer survivors, soy has not been found to decrease menopausal symptoms. There is very little human data on the role of phytoestrogens in preventing breast cancer recurrence, but the few studies conducted do not support a protective role. There is in vivo animal data suggesting the phytoestrogen genistein may interfere with the inhibitive effects of tamoxifen on breast cancer cell growth. (CA Cancer J Clin 2007;57:260–277.) © American Cancer Society, Inc., 2007.

INTRODUCTION

Phytoestrogens are a group of plant-derived substances that are structurally or functionally similar to estradiol.1,2 Interest in phytoestrogens, particularly soy, has been fueled by epidemiologic studies that have suggested low incidence of breast cancer in countries with high soy intake, and this has been followed by in vitro and in vivo animal research suggesting a potential role for phytoestrogens in preventing breast cancer development.1,3,4 Dietary changes present one of the few socially acceptable modifiable risk factors for breast cancer, the second leading cause of cancer deaths in women.5 Hence, even a modest protective role of phytoestrogens could have important implications for public health. In addition to its potential role in preventing breast cancer, there has been much interest in using phytoestrogens for menopausal symptoms among breast cancer survivors. Women diagnosed with breast cancer report more menopausal symptoms than women who undergo menopause naturally,6–8 yet they are generally advised not to use hormone therapy (HT)9 because of concerns that HT may increase risk of recurrence.10,11 Women often seek out complementary and alternative (CAM) therapies in place of HT for menopausal symptoms, particularly phytoestrogens, in the belief they are more “natural.”12,13

There have been concerns that phytoestrogens, through their estrogenic properties, may increase the risk of recurrence or stimulate the growth of existing tumors.14 Despite significant research in the area, the role of phytoestrogens in breast cancer remains controversial. Given the prevalence of CAM therapy use among breast cancer survivors15 and research that suggests women with breast cancer consider soy products safe,16 there is a need to clarify what is known and not known about the risks and benefits of phytoestrogens. Such information is important in enabling patients to make informed decisions about their care.

The purpose of this article is to provide a basic overview of phytoestrogen classification, source, and metabolism and to summarize current evidence regarding the most pressing clinical questions patients and providers may have about phytoestrogens and breast cancer. We review the available evidence regarding (1) the relationship between...
phytoestrogens and primary prevention of breast cancer; (2) the use of phytoestrogens to treat menopausal symptoms in breast cancer survivors; (3) the association between phytoestrogen use and the risk of breast cancer recurrence; and (4) interactions between phytoestrogens and tamoxifen. While not exhaustive, these issues are commonly encountered in clinical practice. Because soy and soy supplements are the most widely used and studied sources of phytoestrogens both worldwide and in the United States, our main focus is on soy, although we also include data on lignans, which are another significant source of phytoestrogens in the US diet.17,18

PHYTOESTROGEN CLASSIFICATION AND METABOLISM

Phytoestrogens are a broad group of plant-derived compounds with the presence of a phenolic ring that allows them to bind to the estrogen receptor (ER), mimicking the effects of estrogen.19 There are 2 major classes of phytoestrogens: the lignans and isoflavones. The coumestans and stilbenes represent 2 additional classes, but are less abundant in the diet and less well-studied.19,20 Lignans exist in many plants, where they form the building blocks for plant cell walls.4 They are found in the woody portions of plants, the seed coat of seeds, and the bran layer in grains.17 Flaxseed is by far the greatest single dietary source of lignans, but whole grains, vegetables, and tea are also significant sources and more typically ingested in the American diet.21 Isoflavones are the most common form of phytoestrogens and are found in a variety of plants, the greatest dietary source being soy.4 Although other legumes such as chick peas and green peas contain isoflavones as well, levels are at least 2 orders of magnitude below soy.24 The amount of phytoestrogen in plants and foods varies considerably based on location of crop, time of harvest and crop conditions, processing, and preparation.2,14 For example, isoflavone content in soybeans can be decreased by more than half simply by boiling.24

The metabolism of lignans is quite complex. Once ingested, they are biotransformed by the action of intestinal microflora and converted to hormone–like compounds with weak estrogenic activity.3,20,25 The main plant lignans are matairesinol and secoisolariciresinol, which are converted to the mammalian lignans enterodiol (EDL) and enterolactone (ENL), respectively, on passage through the gut and subsequent metabolism by gut microflora. Enterodiol can be further metabolized to ENL.17 The main lignan found in blood and urine is ENL, and urinary ENL has been used as a marker for lignan intake.17

Isoflavones have a similarly complex metabolism. The 2 main isoflavones, genistein and daidzein, are present in soy primarily as β-D-glycosides, genistin, and dadzin.19 Glycosidic bonds are hydrolyzed by glucosidases of the intestinal bacteria in the intestinal wall to produce aglycons.26,27 The aglycons are further metabolized to glucuronide conjugates in the intestine and liver.19,28 Daidzein may be metabolized to equol or to O-desmethylyangolensin (O-DMA) and genistein to p-ethyl phenol. The major isoflavones that can be detected in the blood and urine are daidzein, genistein, equol, and O-DMA.4,17,19 The aglycone form of isoflavones is biologically active.29

There is a great deal of individual variability in the metabolism of phytoestrogens.1,17,30–35 Individual differences in gut microflora, use of antimicrobials, intestinal transit time, and genetic polymorphisms all likely contribute to this great variability.14,17,19 For instance, the lignans are metabolized into ENL and EDL via gut bacteria, yet not all individuals are capable of metabolizing lignans into these metabolites. Similarly, only 30% to 50% of adults excrete equol (a metabolite of daidzein).31,34,35 The foods ingested with phytoestrogens can affect their bioavailability, as well. Fiber intake has been shown to correlate positively with serum and urinary levels of phytoestrogen attained in women.36,23 There is also much variability in the phytoestrogen content of dietary supplements. Setchell et al37 analyzed 33 phytoestrogen supplements to determine whether their actual phytoestrogen content matched that of the manufacturers’ claims and found considerable differences between claimed and actual content. Such differences in phytoestrogen metabolism, bioavailability, and content of supplements may account for some of the inconsistent findings of the effects of phytoestrogens in humans.1,38

Soy is the major source of phytoestrogens in most populations and is widely available in the
United States. Approximately 30% of individuals in the United States report using soy products at least monthly.\textsuperscript{39} Despite this, intake of phytoestrogens remains low in the United States (0.15 to 3.0 mg/day)\textsuperscript{40,41} in comparison with East and Southeast Asian countries (20 to 50 mg/day).\textsuperscript{42,43} Many foods available in the American diet contain a wide variety of hidden sources of processed soy (soy protein isolate, soy concentrate) often used as inexpensive fillers in processed foods.\textsuperscript{18} Although the amounts are small, the widespread practice and frequent consumption in US diets of processed foods make them a significant source of the total phytoestrogen intake in US women.

For example, Horn-Ross et al\textsuperscript{41} found that just over 20% of US women’s genistein and daidzen actually comes from doughnut consumption. Table 1 provides values of phytoestrogen contents of selected foods from a North American diet, as adapted from Thompson et al.\textsuperscript{44}

### ESTROGENIC ACTIVITY OF PHYTOESTROGENS

Estrogens have diverse effects throughout the body, attributable in part to their ability to modulate transcription of target genes in a variety of organs.\textsuperscript{45,46} Phytoestrogens are only weakly estrogenic, having 1/10,000 (daidzein) to 1/100

### TABLE 1 Phytoestrogen Content of Foods as Consumed (Wet Weight) per Serving (µg)

| Food Item (100 g Serving) | DAI  | GEN  | MAT | SECO | Total ISO | Total PE |
|---------------------------|------|------|-----|------|-----------|----------|
| Soy products              |      |      |     |      |           |          |
| Soy milk (8.5 oz)         | 2,312.3 | 4,649.1 | 0.5 | 14.4 | 7,390.0   | 7,422.5  |
| Tofu (1/4 cup)            | 2,988.0 | 5,456.1 | 0.3 | 5.8  | 8,677.9   | 8,688.0  |
| Veggie burger (1/4 cup)   | 133.8  | 322.3 | 0.2 | 3.1  | 480.2     | 484.7    |
| Legumes                   |      |      |     |      |           |          |
| Hummus (1/4 cup)          | 0.5  | 5.7  | 9.5 | 1.5  | 8.3       | 605.8    |
| Nuts and oil seeds        |      |      |     |      |           |          |
| Almonds (1/4 cup)         | 0.5  | 5.3  | 0.1 | 26.0 | 6.7       | 48.5     |
| Cashews (1/4 cup)         | 0.5  | 3.5  | 0.1 | 12.8 | 7.5       | 41.5     |
| Flaxseed (1/4 cup)        | 25.0  | 74.5 | 65.9| 161,388.4 | 138.2    | 163,133.6 |
| Sesame seed (1/4 cup)     | 0.9  | 0.7  | 41.8| 2.5  | 3.6       | 2,722.8  |
| Vegetables                |      |      |     |      |           |          |
| Alfalfa sprout (1/4 cup)  | 0.2  | 0.8  | 0.0 | 0.2  | 39.4      | 44.1     |
| Broccoli (1/4 cup)        | N/D  | 0.0  | 0.0 | 1.2  | 0.0       | 18.8     |
| Carrots, raw (1/4 cup)    | 0.0  | 0.0  | 0.0 | 1.4  | 0.1       | 2.2      |
| Garlic (1 tbsp)           | 0.9  | 2.4  | 0.8 | 7.2  | 3.5       | 102.6    |
| Olives (1/4 cup)          | 0.5  | 0.7  | 0.0 | 11.9 | 2.4       | 15.4     |
| Sweet potatoes (1/4 cup)  | 0.1  | 0.1  | 6.3 | 1.6  | 0.2       | 13.9     |
| Tomatoes (1/4 cup)        | 0.0  | 0.1  | 0.0 | 0.5  | 0.2       | 3.9      |
| Winter squash (1/4 cup)   | 0.0  | 0.1  | 0.0 | 4.7  | 0.1       | 39.8     |
| Fruit                     |      |      |     |      |           |          |
| Dried apricots (1/4 cup)  | 2.4  | 7.3  | 0.2 | 54.6 | 14.7      | 164.4    |
| Dried dates (1/4 cup)     | 0.4  | 1.0  | 0.1 | 32.9 | 1.6       | 102.1    |
| Cereals and breads        |      |      |     |      |           |          |
| Bread, multi (1 slice)    | 0.4  | 1.9  | 0.6 | 2,194.4 | 5.8      | 2,207.4  |
| Bread, white (1 slice)    | 0.1  | 0.2  | 0.0 | 0.5  | 0.6       | 1.9      |
| Cereal, high-fiber (1/4 cup) | 0.3  | 0.3  | 0.1 | 3.8  | 0.9       | 9.5      |
| Cereal, regular (1/4 cup) | 0.1  | 0.3  | 0.2 | 1.2  | 0.9       | 2.8      |
| Doughnuts (1 whole)       | 569.6| 961.5| 0.1 | 10.6 | 1,551.0   | 1,568.1  |
| Wine, red (6 oz)          | 2.7  | 4.5  | 0.1 | 61.8 | 29.1      | 94.8     |
| Tea, black (8.5 oz)       | 1.1  | 0.1  | 0.2 | 9.4  | 1.5       | 21.7     |
| Tea, green (8.5 oz)       | 0.9  | 0.4  | 0.4 | 25.4 | 1.7       | 31.6     |

DAI = daidzein.
GEN = genistein.
MAT = matairesinol.
SECO = secoisolariciresinol.
ISO = isoflavone.
PE = phytoestrogen.
N/D = nondetectable.

Adapted from Thompson LU, Boucher BA, Liu Z, et al\textsuperscript{44} with permission from *Nutrition and Cancer*. 
(coumestrol), the activity per mole compared with \(17\beta\) estradiol. Despite this weak activity, concentrations of phytoestrogens in the body are 100 to 1,000-fold higher than peak levels of endogenous estradiol in premenopausal women. In fact, the isoflavone metabolites genistein and daidzein have been shown to exert estrogenic effects even greater than endogenous estradiol at high concentrations in vitro, though these are outside the range of concentrations typically found in humans.

It is difficult to ascertain the estrogenic activity of phytoestrogens in vivo because in addition to the marked interindividual variability in metabolism and, hence, serum levels obtained, the hormonal milieu of the individual consuming the phytoestrogen likely impacts its effects. Another important issue to consider in these studies is the dose of phytoestrogen administered to the animals and how this might affect its actions. De Lemos performed a systematic review of the literature on the effects of genistein on breast cancer cell growth and concluded that at low (\(<10 \mu\)mol/L) physiologically relevant levels, genistein stimulates estrogen receptor positive (ER+) tumors, while at higher (>10 \(\mu\)mol/L) concentrations, genistein appears to be inhibitory. This has been attributed to the estrogenic properties of genistein being predominant at low levels, while at higher levels, other anticancer actions of phytoestrogens predominate. It is important to note, however, that plasma phytoestrogen levels of over 10 \(\mu\)mol/L are difficult to achieve with dietary intake.

The estrogenic activity of phytoestrogens may also depend on their affinity for particular ERs in the body. Phytoestrogens appear to preferentially bind to the ER\(\beta\) and have sometimes been classified as selective ER modulators (SERMs). ER\(\beta\) may play a protective role in breast cancer development by inhibiting mammary cell growth, as well as inhibiting the stimulatory effects of ER\(\alpha\). Phytoestrogens have also been shown to inhibit aromatase, which converts androstenedione and testosterone to estradiol, the target for aromatase inhibitors, which are used to treat postmenopausal breast cancer.

**NONHORMONAL ACTIONS OF PHYTOESTROGENS**

Phytoestrogens also have antitumor activities that are independent of their estrogenic activity. Dietary phytoestrogens have been shown to inhibit proliferation of hormone-independent breast cell lines. This has been postulated to occur via a number of mechanisms, including inhibition or downregulation of protein tyrosine kinases (PTK), which are involved in growth signaling pathways. Genistein has been shown to inhibit PTK, particularly the autophosphorylation and activation of epidermal growth factor receptor, which is important in regulating apoptosis and cell proliferation. Pharmacologic doses of genistein inhibit the PTK-dependent transcription of c-fos and subsequent cellular proliferation in estrogen receptor negative (ER-) human breast cancer cell lines. Other potential mechanisms that have been reported in vitro include phytoestrogen stimulation of the immune system, antioxidant activity, and inhibitory effects on angiogenesis.

**BREAST CANCER PREVENTION**

Interest in phytoestrogens’ effects on breast cancer stemmed from correlational epidemiologic studies indicating the incidence rates of breast cancer are lower in countries that report high consumption of soy foods. In addition, rates of breast cancer among immigrants from countries of high phytoestrogen intake to countries of low intake increase as length of time in the host country increases, suggesting lifestyle changes, including dietary changes in phytoestrogen intake, may play a role. Although intriguing, other dietary or lifestyle changes that occur with immigration to a new country could contribute to these findings.

**STUDIES EXAMINING PHYTOESTROGENS AND BREAST CANCER INCIDENCE**

Many case-control studies have been conducted exploring the role of phytoestrogens in breast cancer risk (see Table 2). Although most case-control studies have indicated some protective effect of soy, findings have been inconsistent, and some have failed to show any relationship between phytoestrogen intake and breast cancer development. There has been some evidence that the menopausal status of a woman may modulate the effects of soy.
### TABLE 2 Case-control Studies Examining Phytoestrogen Intake and Breast Cancer Risk

| Author, Year, and Country of Study | Method of Obtaining Phytoestrogen Intake | Patient Characteristics | Cases/Controls | Results | Comments |
|-----------------------------------|-----------------------------------------|-------------------------|---------------|---------|----------|
| **Dai Q, Shu XO, Jin F, et al,** 1996 to 1998, China (Shanghai) | Interviewer administered FFQ; usual dietary intake | Premenopausal and postmenopausal women aged 25 to 64 years | 1,459 cases cancer registry; 1,556 population-based controls | Reduced breast cancer risk for women in highest decile total soy intake versus lowest decile (OR, 0.66 [0.46 to 0.95]; P for trend = 0.02) | Extensive information on total soy intake; capture 90% of soy intake |
| **Shu XO, Jin F, Dai Q, et al,** 1990 to 1993, China (Shanghai) | Interviewer administered FFQ; usual dietary intake in adolescence (aged 1 to 15 years); also asked mothers their daughters’ soy intake in a subgroup of women; comprehensive measurement of soy intake | Premenopausal and postmenopausal women aged 25 to 64 years | 1,459 cases cancer registry; 1,556 population-based controls | Reduced risk of breast cancer in upper quartile of soy intake during adolescence compared with lowest quartile (OR, 0.75 [0.57 to 0.93]) in premenopausal and postmenopausal women | Extensive information on soy; results unchanged when stratified by usual adult soy intake; low correlation between maternal and study subjects estimates of intake (0.29 cases; 0.30 controls) |
| **Lee HP, Gourley L, Duffy SW, et al,** 1986 to 1988, Singapore (Chinese) | Interviewer using FFQ (soya protein); diet previous year | Premenopausal and postmenopausal Chinese women living in Singapore aged 28 to 83 years | 200 cases; 420 hospital-based controls | Reduced breast cancer risk with increased soya protein intake in highest tertile versus lowest (OR, 0.30 [0.1 to 0.6]); association only seen in premenopausal women | Small numbers |
| **Hirose K, Tajima K, Hamajima N, et al,** 1988 to 1992, Japan | Self-administered FFQ of dietary habits (diet period not specified); bean curd consumption frequency/week | Premenopausal and postmenopausal women >18 years (upper limit not specified) | 1,186 cases outpatient; 21,295 hospital outpatient controls | Reduced risk of breast cancer with bean curd consumption >3 servings/week versus <3 servings/week (OR, 0.81 [0.65 to 0.99]) in premenopausal women | |
| **Wu AH, Ziegler RG, Horn-Ross PL, et al,** 1983 to 1987, United States (Americans of Chinese, Japanese, and Filipo descent) | FFQ; usual adult diet; fresh, dried, deep-fried tofu, miso, and natto | Premenopausal and postmenopausal women aged 30 to 55 years | 597 cases cancer registry; 966 population-based controls | Reduced risk of breast cancer for each additional serving of soy/week (OR, 0.85 [0.74 to 0.99]) | Number of postmenopausal women was small; effect mostly seen in Asian immigrants, not US-born |
| **Yuan JM, Wang QS, Ross RK, et al,** 1984 to 1988, China (Shanghai, Tianjin) | Interviewer administered FFQ; usual adult diet | Premenopausal and postmenopausal women (Shanghai, aged 20 to 69 years; Tianjin, aged 20 to 55 years) | 834 cases population-based cancer registry; 834 community controls | No association of breast cancer risk with soy protein or soy as % total protein; repeated analysis for premenopausal and postmenopausal women the same | Food rationing likely made recall excellent |
| **Zheng W, Dai Q, Custer LJ, et al,** 1996 to 1997, China (Shanghai breast cancer study) | Urinary excretion of isoflavonoids daidzein, genistein, glycitein, equol, and O-DMA (HPLC analysis) | Premenopausal and postmenopausal women aged 25 to 64 years | 60 cases population-based cancer registry; 60 cases from general population | Trend for decreasing breast cancer odds with increasing isoflavone intake, but not statistically significant | No difference in soy intake between cases and controls, suggesting individual metabolism may be important |
| **Ingram D, Sanders K, Kolybaba M, Lopez D,** 1992 to 1994, Australia | Urinary excretion of phytoestrogens daidzein, genistein, equol, enterodiol, and enterolactone | Premenopausal and postmenopausal women aged 30 to 84 years | 144 hospital-based outpatient clinic; 144 controls electoral roll | Increasing equol and enterolactone levels in urine associated with reduced breast cancer risk, but NS (P = 0.13). Similar trends for premenopausal and postmenopausal analysis | Measurement soon after diagnosis could affect gut transit |
| **Murkies A, Dalais FS, Briganti EM, et al,** 2000, Australia (Melbourne) | 24-hour urinary isoflavones, including genistein and daidzein | Postmenopausal women only, age range not stated; mean age 59.3 years | 18 cases from outpatient medical center; 20 cases from mammography | Daidzein excretion significantly lower in cases (P = 0.03); genistein excretion lower in cases, but NS (P = 0.08) | |
TABLE 2  Case-control Studies Examining Phytoestrogen Intake and Breast Cancer Risk (continued)

| Author, Year, and Country of Study | Method of Obtaining Phytoestrogen Intake | Patient Characteristics | Cases/Controls | Results | Comments |
|-----------------------------------|-----------------------------------------|-------------------------|---------------|---------|----------|
| Horn-Ross PL, John EM, Lee M, et al.1995 to 1998, United States (California, non-Asian women) | Interviewer administered FFQ; diet in previous year to diagnosis of 7 phytoestrogen compounds (not named) | Premenopausal and postmenopausal women aged 35 to 79 years | 1,326 population-based cases from cancer registry; 1,657 random-digit dialing matched on age and ethnicity | No association; no change with analysis by menopausal status, individual phytoestrogens, or ethnic groups |
| Wu AH, Wan P, Hankin J, et al.1995 to 1998, United States (Chinese, Japanese, and Filipino women in Los Angeles County) | Interviewer administered diet questionnaire that assessed adult soy intake and adolescent intake (aged 12 to 18 years) | Premenopausal and postmenopausal women aged 25 to 74 years | 501 cases, population-based cancer registry; 594 neighborhood controls matched for ethnicity and age | Risk of breast cancer was decreased with increasing quartiles of soy intake as adult (OR, 0.85 [0.59, 1.24]; OR, 0.80 [0.54, 1.20]; OR, 0.61 [0.39 to 0.97]; P = 0.04 for trend) and as an adolescent (OR, 0.73 [0.47 to 1.14]; OR, 0.62 [0.42, 0.92]; OR, 0.65 [0.38 to 1.10]; P = 0.04 for trend); high soy consumers during adolescence and adulthood had lowest risk (OR, 0.53 [0.36 to 0.78]); results for premenopausal and postmenopausal women were in the same direction, but statistically significant for postmenopausal women |
| Linseisen J, Piller R, Chang-Claude J.1992 to 1995, Germany | Self-administered FFQ; usual intake in previous year; assessed isoflavonoids and lignans | Premenopausal only (defined as age <50 years at diagnosis) | 278 cases, population-based; 666 controls matched by age and study region | Reduced risk of breast cancer in highest versus lowest quartiles of daidzein and genistein (OR, 0.63 [95% CI 0.40 to 0.95]; OR, 0.47 [95% CI 0.29 to 0.74, respectively]); intake of enterodiol and enterolactone were also inversely associated with breast cancer risk (OR, 0.61 [95% CI 0.39 to 0.98] and 0.57 [95% CI 0.35 to 0.92], respectively) |
| Thanos J, Cotterchio M, Boucher BA, et al.2002 to 2003, Canada | Self-administered FFQ; intake between age 10 to 15 years; assessed lignans and isoflavones | Premenopausal and postmenopausal; population-based; women aged 25 to 74 years | 3,024 cases; 3,420 controls matched via random digit dialing matched on age | Decreased breast cancer risk associated with increasing isoflavone, lignan, and total phytoestrogen intake in adolescence; compared with lowest quartile (OR, 0.91 [95% CI 0.79 to 1.04]; OR, 0.85 [95% CI 0.75 to 0.98]; and OR, 0.71 [95% CI 0.63 to 0.82] for quartiles 2, 3, and 4, respectively; P for trend = <0.01) |
| McCann SE, Kulkarni S, Trevisan M, et al.1996 to 2001, United States (New York State, Western New York exposures and breast cancer study) | FFQ from previous 12 to 24 months prior to interview; assessed lignans, isolariciresinol, and metatairesinol | Premenopausal and postmenopausal women aged <65 years | 1,166 cases; population-based 2,105 controls matched on age, race, and county residence | Decreased risk of ER- breast cancer with increasing lignan intake (OR, 0.68 [95% CI 0.36 to 1.26]; OR, 0.62 [95% CI 0.33 to 1.18]; OR, 0.48 [95% CI 0.25 to 0.95] compared with lowest quartile; P for trend = 0.03, but only among premenopausal women) |
| Pillar R, Chang-Claude J, Linseisen J.1992 to 1995, Germany | Plasma enterolactone and genistein | Premenopausal women aged ≤50 years | 220 premenopausal population-based cases; 220 age-matched controls | Decreased risk of premenopausal breast cancer with increasing plasma enterolactone (OR, 0.42 [95% CI 0.20 to 0.90]; OR, 0.35 [95% CI 0.17 to 0.85] for the upper 2 quartiles of intake [lowest as ref]; P = 0.007 for trend) |

FFQ = food frequency questionnaire.
HPLC = high performance liquid chromatography.
OR = odds ratio.
NS = not significant.
CI = confidence interval.
ER+ = estrogen receptor positive.
ER- = estrogen receptor negative.
Case–control studies have generally found more evidence for a protective role in premenopausal women versus postmenopausal. This lends support to a current hypothesis that phytoestrogens’ effects are dependent on the hormonal status of the woman, with stimulatory effects in low-estrogen environments, while in high-estrogen states, they may block the effects of estrogen.89,90

In contrast, most prospective cohort studies (Table 3) have failed to show any relationship between soy intake and breast cancer risk.91–93,96 One prospective cohort study among premenopausal and postmenopausal Japanese women aged 40 to 59 years that specifically asked about miso soup, soybeans, tofu, and natto did suggest a protective effect of increasing quartiles of isoflavone intake.94 Another prospective cohort study with premenopausal and postmenopausal women aged 45 to 75 years from the United Kingdom found an increased risk of breast cancer with increasing urinary and serum isoflavone levels in this population, although intake was quite low (<1 mg/day).95 A recent meta-analysis97 of cohort and case–control studies examining soy intake and breast cancer risk found that high versus low soy intake was associated with a small reduced breast cancer risk (odds ratio [OR] 95%, confidence interval [CI] 0.75 to 0.99). In this meta-analysis, the protective effect of soy consumption on breast cancer risk appeared to be stronger among premenopausal women. However, the researchers noted a high degree of heterogeneity among studies and lack of a dose–response relationship between soy and breast cancer risk. In addition, the methods of measuring and categorizing soy were different among the studies. The classification of high versus low soy intake in the meta-analysis was based on the cutpoints chosen by the authors of each study and, hence, was not standardized. In addition, the populations studied were different and, hence, food sources of phytoestrogen differed. Such methodological differences among studies make it difficult to pool results and interpret findings.

While there are fewer studies examining the effect of lignans, the other major source of phytoestrogens in the US diet,41 on breast cancer development, most studies have suggested a protective role of high lignan intake85,96,98,99 or in those who have higher serum or urinary levels of the main lignan metabolites, ENL and EDL.82,88,100,101 However, a few studies have failed to show a relationship between lignan biomarkers and breast cancer.92,95,102 Nearly all studies were conducted in non-Western populations. One prospective cohort study among premenopausal and postmenopausal women in the United States indicated an increased risk of breast cancer associated with higher dietary lignan intake,93 but lignan intake was relatively low in this population.

The epidemiologic studies exploring phytoestrogen intake and breast cancer risk are subject to a number of methodological limitations. All the retrospective case–control studies are subject to important biases. Recall bias after a cancer diagnosis is a major concern, but there may also be changes in dietary habits after a diagnosis, colonic transit changes related to stress, or antibiotic use (which alters colonic bacteria) associated with treatment and complications of a cancer diagnosis. For non-Asian populations, intake may be too low to differentiate meaningful exposure levels among individuals, and in populations of high consumers of phytoestrogens, uniformly high intakes may present similar problems. Measurement of phytoestrogens, either by food frequency questionnaire or by urinary excretion, is imprecise, as well.

**PHYTOESTROGENS AND MARKERS OF BREAST CANCER RISK**

It is generally accepted that higher lifetime estrogen exposure is associated with increased breast cancer risk.103–105 Some researchers have examined the relationship between phytoestrogens and endogenous hormone levels. Concentrations of 17β-estradiol are approximately 40% lower in Asian women compared with their Caucasian counterparts,51,106 but whether this is due to high phytoestrogen intake is not clear. While some studies have shown that phytoestrogen intake is associated with decreased estradiol levels107–111 or estrogen metabolites,112 many have failed to show any association.113–115 In a substudy of the European Prospective Investigation into Cancer and Nutrition study, investigators examined the relationship between the major phytoestrogens (as measured by urine,
TABLE 3  Cohort Studies Examining Phytoestrogen Intake and Breast Cancer Risk

| Study | Method of Obtaining Soy | Patient Characteristics | Number of Study Cases/Participants | Results | Comments |
|-------|-------------------------|-------------------------|------------------------------------|---------|----------|
| Key TJ, Sharp GB, Appleby PN, et al,91 nested case control, 1969 to 1993, Japan, women from Radiation Effects Research Foundation’s Life Span Study | Mailed questionnaire of dietary consumption of 19 foods, including miso soup, tofu | Throughout life span, individuals living in Nagasaki or Hiroshima | 427/43,759 | No association; repeated analysis for premenopausal and postmenopausal the same | Women with radiation exposure; limits generalizability |
| den Tonkelaar I, Keinan-Boker L, Veer PV, et al,92 nested case control, 1977 to 1985, Netherlands, selected from cohort of women in a population-based breast cancer screening program | Urinary enterolactone and genistin | Postmenopausal women; aged 50 to 64 years | 88/268 from total population of 14,697 | No significant association; test for trend NS | Women selected from a breast cancer screening program; limits generalizability |
| Horn-Ross PL, Hoggatt KJ, West DW, et al,93 1995 to 1997, California teacher’s study | Self-administered block FFQ; intake year prior to baseline; phytoestrogen content estimated from responses | Premenopausal and postmenopausal, aged 21 to 103 years | 711/111,526 | No association between phytoestrogen consumption and breast cancer risk | Participants from one state only; limits generalizability |
| Yamamoto S, Sobue T, Kobayashi M, et al,94 1990 to 1999, Japan, The Japan Public Health Center-Based Prospective Study on Cancer and Cardiovascular diseases | Self-administered FFQ that specifically asked about habitual miso soup and “soybeans, tofu, deep-fried tofu, and natto” | Premenopausal and postmenopausal, aged 40 to 59 years | 179/21,852 | Decreased risk of breast cancer with increasing quartile of isoflavone intake and miso soup; no relationship with soy foods | Stronger association in postmenopausal women; miso soup and soya food accounted for 80% of isoflavone intake |
| Grace PB, Taylor JI, Low YL, et al,95 nested case-control study, 1993 to 2001, United Kingdom, Norfolk cohort of the European prospective investigation into cancer and nutrition | Urinary daidzein, genistein, glycitein, equol, enterodiol, and enterolactone | Premenopausal and postmenopausal; aged 45 to 75 years | 114/13,070 | Urinary and serum isoflavone levels were associated with increased risk of breast cancer, statistically significant for equol and daidzein; for a doubling of level, log2 (OR, 1.34 [95% CI 1.06 to 1.70]) for urine equol; (1.46 [95% CI 1.05 to 2.02]) serum equol; and (1.22 [95% CI 1.01 to 1.48]) for serum daidzein | Dietary intake of isoflavones was low |
| Keinan-Boker L, van Der Schouw YT, Grobbee DE, Peeters PH,96 1993 to 2001, Netherlands, Dutch cohort of the European prospective investigation into cancer and nutrition | Self-administered FFQ; previous year | Premenopausal and postmenopausal women; aged 49 to 70 years | 280/15,555 | No relationship between isoflavone and lignans and breast cancer risk; test for trend negative | Dietary intake was low |

FFQ = food frequency questionnaire.
OR = odds ratio.
NS = not significant.
CI = confidence interval.
Implications of Phytoestrogen Intake for Breast Cancer

Phytoestrogens and Menopausal Symptoms

Breast cancer treatment, including chemotherapy and/or hormonal therapy, may induce or accelerate ovarian failure. Breast cancer survivors who experience chemotherapy-related ovarian failure report high levels of menopausal symptoms. The results of the HABITS (Hormone therapy after breast cancer—is it safe?) trial suggested an increased risk of recurrence in women who use exogenous HT, and hence, women with breast cancer are generally advised to avoid exogenous HT. A history of breast cancer remains a black-box warning on hormonal agents, even treatments with low systemic exposure to estrogen such as estradiol vaginal rings. Although other medications, such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), clonidine, and gabapentin, have been shown to significantly reduce the frequency and intensity of hot flashes, soy supplementation may be an attractive dietary alternative for women who have had breast cancer and have been advised against the use of HT. Dietary supplements and dietary changes are often viewed as “natural,” and in fact, breast cancer survivors report high use of CAM. In a telephone survey of breast cancer survivors, over 10% were increasing the amount of soy in their diet to treat menopausal symptoms. This is concerning given the lack of data to support soy as a treatment for these symptoms.

Four randomized placebo-controlled trials have been conducted investigating the use of isoflavones to treat menopausal symptoms in breast cancer survivors (see Table 4). None of the 4 studies of women who received oral isoflavone supplementation showed any significant treatment effect on hot flash symptoms. All studies used soy tablets and reported isoflavone content, except one that used a soy drink with isoflavone added. Methods of measuring hot flashes varied across studies, and no study included supplementation for longer than 12 weeks. These disappointing results are in agreement with 2 recent reviews of CAM therapies for menopausal symptoms, both of which found little evidence...
that phytoestrogens are an effective treatment of menopausal symptoms in women without a history of breast cancer.\textsuperscript{136,137} Two RCTs of black cohosh (a phytoherb sometimes classified as a phytoestrogen) also failed to provide significant benefit with regard to menopausal symptom management in women with breast cancer.\textsuperscript{134,135}

### PHYTOESTROGENS AND BREAST CANCER SURVIVORS

#### Recurrence

There has been great interest by clinicians and breast cancer survivors in the potential for phytoestrogens to reduce the risk of breast cancer recurrence. Unfortunately, almost all data to guide patients and clinicians are from observational epidemiologic studies or based on in vitro and animal models. In a population-based case-control study in China (a follow up of the Shanghai Breast Cancer Study) designed to explore risk factors associated with breast cancer, soy intake before cancer diagnosis was unrelated to disease-free breast cancer survival. A subgroup analysis to determine whether postdiagnosis change in soy food consumption altered breast cancer risk found no support for an association,\textsuperscript{138} though the study was neither designed

---

### TABLE 4  RCT Using Phytoestrogens to Treat Menopausal Symptoms in Breast Cancer Survivors

| Author, Year | Isoflavone Content | Study Inclusion Criteria | Length of Trial | Outcomes Measure | Results | Comments |
|--------------|--------------------|--------------------------|-----------------|-----------------|---------|----------|
| MacGregor CA, Canney PA, Patterson G, et al,\textsuperscript{130} 2004 | 35 mg/day | Aged >18 years; histologically confirmed pre-existing breast cancer; menopausal score >1; concomitant or preceding adjuvant therapy allowed | 12 weeks | EORTC QL: Q-C30 questionnaire, Breast Cancer Module BR23, and menopausal scale | No difference | No significant difference in global quality of life scores |
| Nikander E, Kikkinen A, Metsa-Heikkila M, et al,\textsuperscript{131} 2003 | 114 mg/day | Postmenopausal women who had been treated for breast cancer; no residual disease; incapacitating hot flashes, night sweats, and sleeplessness; FSH >30 U/L | 3 months | Kupperman Index and 10-cm-long visual analogue scale | No difference | Blood samples were taken after an overnight fast on the first day and on the last day of treatment |
| Van Patten CL, Olivotto IA, Chambers GK, et al,\textsuperscript{132} 2002 | 90 mg/day | 4 months post-treatment: no HT for 4 months; stratified by tamoxifen; 59 soy beverage, 63 controls | 12 weeks | Daily menopause diary, number of hot flashes on 5-point scale; converted to 24-hour score | No difference | Genistein serum levels were higher, but not daidzein; GI side effects; compliance high |
| Quella SK, Loprinzi CL, Barton DL, et al,\textsuperscript{133} 2002, 118 RCT | 150 mg/day | Women aged >18 years; >4 months post-treatment: 14 hot flashes/week; tamoxifen allowed; 177 women soy | 4 weeks | Hot flash frequency and intensity via questionnaire; converted to weekly hot flash scores | No difference | Self-reported compliance high |

RCT = randomized controlled trial.
FSH = follicle-stimulating hormone.
HT = hormone therapy.
GI = gastrointestinal.
nor powered to detect differences in survival related to phytoestrogen intake. One RCT examined the impact of dietary flaxseed on markers of tumor cell growth and proliferation in postmenopausal breast cancer patients. They found 25 g/day of flaxseed reduced cell proliferation, increased apoptosis, and reduced c-erbB2 expression of human breast cancer cells in biopsy tissue between time of diagnosis and time of definitive breast surgery. However, no RCTs have specifically studied whether phytoestrogen supplementation reduces the risk of breast cancer recurrence.

**ANIMAL MODELS**

Many studies have explored the role of phytoestrogens in breast cancer using rodent models of breast cancer initiation and growth. Animals genetically bred to develop breast cancer or the use of a chemical carcinogen administered to the animals have both been used to study the effects of phytoestrogens on breast cancer tumorigenesis. Researchers have also used human breast cancer cell lines (mostly MCF-7, which are ER+ breast cancer cells) injected into laboratory animals and then modulated the animal’s diet with phytoestrogens. While none of these models captures the complexities of a human model for breast cancer initiation and growth, the last model is probably most applicable to breast cancer survivors’ consumption of phytoestrogens and risk of recurrence.

Concerns regarding safety of phytoestrogen consumption have been raised as several studies have indicated phytoestrogens could play a stimulatory role in breast cancer growth. Allred et al found that diets containing increasing amounts of soy stimulated growth of estrogen-dependent tumors in a dose-dependent manner. The plasma levels of genistein reached in the rats were 2 µmol/L, which is similar to levels measured in women who drink soy-milk. Similarly, Ju et al found that physiologic levels of genistein stimulate MCF-7 breast cancer cells implanted into a novel animal model with low circulating levels of estradiol (which models postmenopausal breast cancer).

However, many studies have indicated an inhibitory effect of soy or isoflavones on transplanted breast cancer cell growth and metastasis using rodent models. Constantinou et al found that in vitro genistein treatment of MCF-7 breast cancer cells (ER+), as well as MDA-MB-468 cells (ER-), reduced the tumorigenicity of both cell lines in athymic mice. Yan et al examined the effect of soy supplementation on metastasis of the highly metastatic 4526 murine mammary carcinoma cell line implanted into BALB/c mice and found a 26% reduction in metastasis in the soy-fed group. The majority of studies that have found a protective effect of isoflavones have been animal studies involving chemically induced tumors with 7,12-dimethylbenz(a)anthracene (DMBA). The applicability of these findings to breast cancer survivors remains uncertain.

**TIMING OF EXPOSURE**

Researchers have postulated that timing of dietary estrogenic exposures influences whether the exposure increases or decreases subsequent breast cancer risk. For instance, prepubertal exposure to genistein decreases the risk of mammary tumorigenesis in female rats, while exposure in utero increased risk of tumors developing in the offspring or had no effect. Studies evaluating adult rat exposure to genistein have failed to find a protective effect. Lamartiniere et al demonstrated that exposure of prepubertal rats to genistein before the administration of the carcinogen (DMBA) was protective against mammary cancer. In rats treated neonatally with genistein, mammary glands were larger, there were more terminal end buds and terminal ducts, and more proliferative activity in all terminal ductal structures. It appeared that neonatal genistein treatment exerted its chemoprevention by acting directly to enhance maturation of terminal ductal structures and by altering the endocrine system to reduce cell proliferation in the mammary gland. Lamartiniere concluded that prenatal-only exposure to genistein is not sufficient to protect against mammary cancer in the rat model and that genistein exposure must occur prepubertally to exert a chemoprotective effect.

There is some human data from case-control studies to support the hypothesis that timing of
phytoestrogen exposure may influence its effects. Shu et al.,76 in a population of Asian women, found that women who consumed higher amounts of tofu between the ages of 13 to 15 years were less likely to develop both premenopausal and postmenopausal breast cancer. Similarly, Wu et al.84 conducted a case-control study in an Asian premenopausal and postmenopausal population living in the United States and found that adolescent exposure to soy was protective against developing breast cancer as an adult. Thanos et al.86 in a population of Canadian premenopausal and postmenopausal women, found that adolescent intake of both isoflavones and lignans was protective of breast cancer development later in life. Women who consumed high phytoestrogens in both early (adolescent) and later life (adult) actually had the lowest risk of breast cancer.

How such studies should be interpreted for breast cancer survivors is difficult to ascertain. If protective effects are conferred only with prepubertal exposure to phytoestrogens, then there may be no justification for increasing phytoestrogen intake in adult women in Western countries since their prepubertal intake can be expected to be quite low. Increasing soy (with its potential to stimulate growth) may not be prudent. More research is needed to clarify how the timing of phytoestrogen exposure impacts protective effects on breast cancer development and growth.

PROCESSING AND COADMINISTRATION

In addition to timing of the phytoestrogen exposure, processing and agents coadministered with phytoestrogens may impact their actions. Allred et al.157 examined the effect of various soy products on growth of MCF-7 cells transplanted into ovariectomized athymic mice. Products investigated included soy flour and 2 crude extracts of soy (soy molasses and a commercially available mixture of isoflavones and genistein in pure form). The soy flour did not stimulate breast cancer cell growth, while the extracts and pure forms stimulated growth. The researchers commented that soy flour is the more commonly consumed form of soy in Asian countries and concluded that consuming less-processed soy formulations such as soy flour rather than purified forms may be advisable. Saarinen et al.158 has examined the effect of flaxseed on the stimulatory effects of soy protein on MCF-7 breast cancer cells in ovariectomized athymic mice and found that flaxseed appears to eliminate any stimulatory effect of soy on breast cancer growth.

Studies involving ENL, the major lignan, have been fewer, but have indicated growth inhibition of existing breast cancer tumors in animals,159–164 although in vitro at low doses, ENL has stimulated breast cancer cell growth in at least one study.165

LIMITATIONS OF ANIMAL MODELS

While there are many similarities in mammary gland development in rodents and humans (differentiation to form lobules and terminal end-bud structures at puberty; further maturation of breast cells during pregnancy and lactation), there are important limitations of using animal models to predict the effects of isoflavones14,166 or lignans167 in humans. For instance, while the gut flora of rats are able to metabolize large quantities of daidzein to equol, only a quarter of women contain the gut flora necessary to metabolize daidzein to equol.166 In addition, the equol produced is the S-enantiomer in humans and binds preferentially to ERβ. Whether this is the case in rodents is not known yet.166 In addition, Allred et al.27 have found that soy processing of rodent diets affects the levels of aglycon (bioactive form) genistein produced by the animals, and phytoestrogens added to rodent diets are not standardized in studies. All these issues suggest caution is warranted when extrapolating available animal data to humans.

ADJUVANT HORMONAL TREATMENTS AND PHYTOESTROGENS

Tamoxifen

Although aromatase inhibitors are increasingly being used in early stage breast cancer, tamoxifen remains the first-line hormonal adjuvant therapy for premenopausal women and is one of the first-line hormonal adjuvant treatments recommended by the National Comprehensive Cancer Network for treatment of hormone-positive postmenopausal breast cancer (http://www.nccn.org/profession als/physician_gls/PDF/breast.pdf). Additionally,
it is the only Food and Drug Administration-approved medication for the prevention of breast cancer. However, it is associated with high levels of vasomotor symptoms. Concern that breast cancer survivors on tamoxifen may seek out phytoestrogens for the treatment of these symptoms has prompted investigators to explore the role of phytoestrogens in modulating the effects of tamoxifen on breast cancer cell growth. In particular, there has been concern that soy may abrogate inhibition of tumor growth by tamoxifen. Although no studies in humans have been conducted, there have been some in vitro studies suggesting genistein interferes with tamoxifen’s antiproliferative activity in ER+ breast cancer cell lines. Additionally, in animal models using ovariectomized athymic mice implanted with MCF-7 breast cancer cell lines and MMTV-wt-erbB-2/neu transgenic mice, genistein has been found to interfere with the antiestrogen effects of tamoxifen. However, in Sprague–Dawley rats fed the combination of daidzein and tamoxifen, there was decreased tumor burden. Other in vivo animal-feeding studies using miso and flaxseed have shown potentiation of tamoxifen’s antitumor effects. These studies are summarized in Table 5.

| Author, Year | Cell Line/Animal | ER Status | Phytoestrogen | Results |
|--------------|------------------|-----------|---------------|---------|
| Zava DT, Duwe G, 1997 | MCF-7 T47D; MDA-468 | ER+; ER- | Genistein | ER+: at low doses, tamoxifen did not block the stimulatory effects of genistein; ER-: genistein was inhibitory on cell growth |
| Gotoh T, Yamada K, Ito A, et al, 1998 | Sprague-Dawley rats | ER+ | Miso | Mean tumor size from pretreatment was smaller in miso and tamoxifen group (85%) versus tamoxifen only (141%) versus control (160%) |
| Schwartz JA, Liu G, Brooks SC, 1998 | Transiently infected HeLa cells | ER+ | Genistein | Low physiological concentrations of genistein were sufficient to reverse effects of 4-hydroxy-tamoxifen on ERα-responsive reported genes |
| Shen F, Xue X, Weber G, 1999 | MDA-MB-435 breast cell lines | ER+ | Genistein | Synergisms in growth inhibition and cytotoxic effects when tamoxifen was added to genistein |
| Ju YH, Doerge DR, Allred KF, et al, 2002 | MCF-7 implanted in ovariectomized athymic mice | ER+ | Genistein | Genistein negated the inhibitory effects of tamoxifen; increased expression of estrogen-responsive genes |
| Liu B, Edgerton S, Yang X, et al, 2005 | MCF-7; wt-erbB-2 transgenic mice | ER+ | Genistein | Low-dose genistein coadministered with tamoxifen resulted in higher tumor formation than those fed high-dose isoflavone, soy, or milk protein-based diet; low-dose genistein and tamoxifen resulted in growth stimulation of mammary cell lines and MCF-7, while high-dose genistein resulted in inhibition of growth |
| Constantinou AI, White BE, Tonetti D, et al, 2005 | Sprague-Dawley rats given DMBA | Genistein and daidzein | Daidzein and tamoxifen had reduced tumor multiplicity, while genistein and tamoxifen had increased tumor multiplicity as compared with tamoxifen alone |

ERα = estrogen receptor alpha.
ER+ = estrogen receptor positive.
ER- = estrogen receptor negative.
Such conflicting data make interpretation difficult. It may be that the level of isoflavone concentration reached is important, as noted earlier. At low levels, genistein acts as a weak estrogen, partially displacing tamoxifen from the ER, while at higher doses, genistein’s effects may be estrogen independent and act synergistically with tamoxifen. How the results of these studies should be applied to human breast cancers is still controversial, but the results do raise concerns about the safety of consuming soy products, and some have recommended women with breast cancer who are on tamoxifen not consume soy or consume cautiously, while others have suggested women can consume soy products safely.

Whether phytoestrogens might interfere with the inhibitory effects of the aromatase inhibitors is not known. Both isoflavones and lignans have been shown to inhibit aromatase weakly in vivo. One study examined whether formestane’s (an aromatase inhibitor) actions on tumor growth were altered by the coadministration of black cohosh. Formestate reduced estrogen levels by 50%, regardless of coadministration with black cohosh, suggesting no interaction between the two. Clarifying whether phytoestrogen intake might alter the effectiveness of aromatase inhibitors is an important area for further research, given their increasing use.

**SUMMARY AND RECOMMENDATIONS**

Research suggests that the relationship between phytoestrogens and breast cancer is not straightforward. There is evidence for both a protective role and a stimulatory role in breast cancer cell growth. The nature of the relationship between phytoestrogens and breast cancer likely depends on a number of factors, including the timing of the phytoestrogen exposure, individual differences in metabolism, hormonal milieu, whether phytoestrogens are consumed as food or as supplement, and the growing conditions and processing practices for the plants that contain phytoestrogens.

Both in vitro studies with breast cancer cell lines and in vivo animal studies suggest the timing of exposure to phytoestrogens may be a key component in determining its effects, with animal data consistent with a protective effect of soy prepubertally. Epidemiologic studies in humans support this hypothesis with studies showing adolescent soy exposure appears to be protective, while the studies examining the effects of adult exposure and risk of breast cancer are quite heterogeneous. Heterogeneity across epidemiologic studies of phytoestrogen intake and breast cancer risk is likely related to difficulties in measuring phytoestrogen exposure (especially in Western diets). Caution is warranted in interpreting results of such epidemiologic studies since most were conducted in Asian countries. Genetic differences in phytoestrogen metabolism and estrogen exposure, as well as early life exposure to phytoestrogens, make extrapolation to non-Asian populations questionable.

There is no compelling evidence that phytoestrogens help menopausal symptoms, and given potential concerns for stimulating breast cancer cell growth, it should not be recommended for use to treat these symptoms in this population.

Although not definitive, research suggesting genistein stimulates breast cancer cell growth in in vivo animal models suggests women should be advised against claims that soy is a “safe” estrogen product and informed that some research indicates it could increase risk of recurrence. Women should be informed of the conflicting data in this regard and the lack of good-quality studies (placebo-controlled randomized trials) that directly address this issue. In particular, women on tamoxifen should be cautioned against the use of soy supplements and purified products. While data are insufficient to conclusively say that supplements are less beneficial (or more harmful) than dietary phytoestrogen intake, research suggests that these processed products may have detrimental effects compared with soy flour and tofu (sources most commonly consumed in Asian countries with low incidence of breast cancer). The consumption of high-dose isoflavone supplements by women at high risk or by breast cancer survivors cannot be recommended. Several recent reviews are in agreement with this recommendation.

There is less evidence to guide intake of other phytoestrogens, such as lignans, but current research suggests they may play a protective role. Also, lignans do not appear to interfere with
Implications of Phytoestrogen Intake for Breast Cancer

Several federally funded trials are currently being conducted to try to answer some of the unanswered questions regarding phytoestrogens and breast cancer. These include (1) a randomized placebo-controlled trial of oral genistein in preventing breast cell proliferation in high-risk women (NCT 00240758); (2) a randomized placebo-controlled trial examining the effect of soy supplement pills on premenopausal breast density (NCT00204490); (3) a dietary intervention with soy meal replacement drinks among breast cancer survivors to assist with weight loss (NCT 00343434); and (4) a Phase II trial to add genistein to the chemotherapy agent gemcitabine in Stage IV breast cancer patients (NCT 00244933).

Consuming naturally occurring soy products such as tofu or soy flour as part of a balanced diet low in saturated fats and high in fruits and vegetables is likely safe and perhaps even beneficial. Emerging evidence suggests that avoiding weight gain after a breast cancer diagnosis may help prevent recurrence. To the extent that phytoestrogens may be found in such a diet, such intake is likely safe, although supplemental intake or augmentation of dietary phytoestrogen sources cannot be recommended at this time.

REFERENCES

1. Limer JL, Speirs V. Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res 2004; 6:119–127.
2. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Obstet Gynecol 1996; 87:897–904.
3. Murkies AL, Wilcox G, Davis SR. Clinical review 92: Phytoestrogens. J Clin Endocrinol Metab 1998;83:297–303.
4. Tham DM, Gardner CD, Haskell WL. Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 1998;83:2223–2235.
5. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.
6. Carpenter JS, Andrykowski MA. Menopausal symptoms in breast cancer survivors. Oncol Nurs Forum 1999;26:1311–1317.
7. Couri RJ, Heldsinger KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1995;13: 2737–2744.
8. Ganz PA, Rowland JH, Desmond K, et al. Life history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1998;16:501–514.
9. Bruno D, Feeney KJ. Management of postmenopausal symptoms in breast cancer patients. Oncol Nurs Forum 1999;26:1311–1317.
10. Cournet RJ, Heldsinger KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1995;13: 2737–2744.
11. Chlebowski RT, Anderson GL. Progestins and recurrence in breast cancer survivors. J Natl Cancer Inst 2005;97:471–472.
12. Lee MM, Lin SS, Wrensch MR, et al. Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst 2000;92:42–47.
13. Morris KT, Johnson N, Homer L, Wahl D. A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 2000;179:407–411.
14. Messina M, McCaskill-Stevens W, Lampe JW. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst 2006;98:1275–1284.
15. Nahleh Z, Tabbara IA. Complementary and alternative medicine in breast cancer patients. Palliat Support Care 2003;1:267–273.
16. Harris PF, Remington PL, Trentham-Dietz A, et al. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 2002;33:501–509.
17. Webb AL, McCullough ML. Dietary liguans: potential role in cancer prevention. Nutr Cancer 2005;51:117–131.
18. Horn-Ross PL, Barnes S, Lee M, et al. Assessing phytoestrogen exposure in epidemiologic studies: development of a database (United States). Cancer Causes Control 2000;11:289–298.
19. Setchell KD. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 1998;68(suppl): 1335S–1346S.
20. Sirtori CR, Arnoldi A, Johnson SK. Phytoestrogens: end of a tale? Am J Med 2005;13:423–438.
21. Cornwell T, Cobbart W, Raskin I. Dietary phytoestrogens and health. Phytochemistry 2004;65: 995–1016.
22. Messina MJ, Loprinzi CL. Soy for breast cancer survivors: a critical review of the literature. J Nutr 2001;131(suppl):3095S–3108S.
23. Dixon RA. Phytoestrogens. Annu Rev Plant Biol 2004;55:225–261.
24. Liggins J, Bluck LJ, Runswick S, et al. Daidzein and genistein contents of vegetables. Br J Nutr 2000;84:717–725.
25. Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med 1997;29:95–120.
excretion of lignans and isoflavonic phytoestrogens, and plasma non-protein bound sex hormones in relation to breast cancer, in Bresciani F, King RJJ, Lippman ME, Raynaud J-P (eds). Progress in Cancer Research and Therapy: Hormones and Cancer. Vol. 3. New York, NY: Raven Press; 1988: 409–412.

37. Setchell KD, Brown NM, Desai P, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001;131(suppl):1362S-1375S.

38. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equal—a clue to the effectiveness of soy and its isoflavones. J Nutr 2002;132:3577–3584.

39. United Soybean Board. Consumer Attitudes About Nutrition: Insights into Nutrition, Health and Soyfoods. Available at: [http://www.talksoy.com/pdfs/ConsAtt_v1r8m1.pdf]. Accessed June 22, 2007.

40. Horn-Ross PL, John EM, Lee M, et al. Phytoestrogen consumption and breast cancer risk in a multiracial population: the Bay Area Breast Cancer Study. Am J Epidemiol 2001;154:434–441.

41. Horn-Ross PL, Lee M, John EM, Koo J. Sources of phytoestrogen exposure among non-Asian women in California, USA. Cancer Causes Control 2000;11:299–302.

42. Chen Z, Zheng W, Custer LJ, et al. Usual dietary consumption of soy foods and its correlation with the excretion rates of isoflavonoids in overnight urine samples among Chinese women in Shanghai. Nutr Cancer 1999;33:82–87.

43. Nagata C, Kabuto M, Kuros K, Shimizu H. Decreased serum estradiol concentration associated with high dietary intake of soy products in premenopausal Japanese women. Nutr Cancer 1997;29:228–233.

44. Thompson LU, Boucher BA, Liu Z, et al. Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans, and coumestol. Nutr Cancer 2006;54:184–201.

45. Kuiper GG, Carlson B, Grandien K, et al. Comparison of binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863–870.

46. Zhai BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998;19:1–27.

47. Anderson JB, Anthony M, Messina M, Garner SC. Effects of phyto-oestrogens on tissues. Nutr Res Rev 1999;12:75–116.

48. Santell RC, Chang YC, Nair MG, Helferich WS. Dietary genistein exerts estrogenic effects upon the uterus, mammary gland and the hypothalamic/pituitary axis in rats. J Nutr 1997;127:263–269.

49. Wang TT, Sathiamoorthy N, Phang JM. Molecular effects of genistein on estrogen receptor-mediated pathways. Carcinogenesis 1996;17:271–275.

50. Zava DT, Duwe G. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer 1997;27:31–40.

51. Goldin BR, Adlercreutz H, Gorbach SL, et al. The relationship between estrogen levels and diets of Caucasian American and Oriental immigrant women. Am J Clin Nutr 1986;44:945–953.

52. Freyberger A, Schmuck G. Screening for estrogenicity and anti-estrogenicity: a critical evaluation of an MVLN cell-based transactivation assay. Toxicol Lett 2005;155:1–13.

53. Kuiper GG, Lemmen JG, Carlson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139:4252–4263.

54. Totta P, Aconcia F, Virgili F, et al. Daidzein-sulfate metabolites affect transcriptional and antiproliferative activities of estrogen receptor-beta in cultured human cancer cells. J Nutr 2005;135:2687–2693.

55. Cassidy A, Albertazzi P, Lise Nielsen I, et al. Critical review of health effects of soybean phytoestrogens in post-menopausal women. Proc Nutr Soc 2006:65:76–92.

56. de Lemos ML. Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. Anim Pharmacother 2001;35:1118–1121.

57. An J, Tzagarakis-Foster C, Scharschmidt TC, et al. Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 2001;276:17808–17814.

58. Brzezinska A, Debi A. Phytoestrogens: the “natural” selective estrogen receptor modulators? Eur J Obstet Gynecol Reprod Biol 1999;85:47–51.

59. Strom A, Hartman J, Foster JS, et al. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004;101:1566–1571.

60. Rice S, Mason HD, Whitehead SA. Phytoestrogens and their low dose combinations inhibit estrogen and progestin receptors in cultured human cancer cells. J Nutr 2005;135:2687–2693.

61. Dampier K, Hudson EA, Howells LM, et al. Regulation of c-fos transcription by chemotherapeutic agents. Biofactors 2000;12:209–215.

62. Kousidou O, Tzanakakis GN, Karamanos NK. Estrogenicity and anti-estrogenicity: a critical evalua-
Implications of Phytoestrogen Intake for Breast Cancer

85. Linseyen J, Piller R, Herrmann S, Chang-Claude J. German Case-Control Study. Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study. Int J Cancer 2004;110:284–290.

86. Thanos J, Cotterchio M, Bouchez BA, et al. Adolescent dietary phytoestrogen intake and breast cancer risk (Canada). Cancer Causes Control 2006;17:253–261.

87. McCann SE, Kulkarni S, Trevisan M, et al. Dietary lignans and risk of breast cancer by tumor estrogen receptor status. Breast Cancer Res Treat 2006;99:309–311.

88. Piller R, Chang-Claude J, Linseyen J. Plasma enterolactone and genistein and the risk of premenopausal breast cancer. Eur J Cancer Prev 2006;15:225–232.

89. Ju YH, Allred KE, Allred CD, Helfrich WG. Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis 2006;27:1292–1299.

90. Adlercreutz H. Phyto-oestrogens and cancer. Lancet Oncol 2002;3:364–373.

91. Key TJ, Sharp GB, Appleby PN, et al. Soya foods and breast cancer risk: a prospective study in Hiroshima and Nagasaki, Japan. Br J Cancer 1999;81:1248–1256.

92. den Tonkelaar I, Keinan-Boker L, Veer PV, et al. The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in young women. J Nutr 2002;132:3036–3041.

93. Horn-Ross PL, Hoggatt KJ, West DW, et al. Adolescent dietary phytoestrogen intake and breast cancer risk (Canada). Cancer Causes Control 2006;17:1253–1261.

94. Yamamoto S, Sobue T, Kobayashi M, et al. Effects of soy-protein supplementation with a soya diet containing isoflavones. Cancer Res 1999;60:1299–1305.

95. Lu LJ, Cree M, Josyula S, et al. Increased urinary excretion of 2-hydroxyestrone but not 16alpha-hydroxysterone in premenopausal women during a soya diet containing isoflavones. Cancer Res 2000;60:1299–1305.

96. Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer 2002;94:1166–1174.

97. Thomas HV, Keeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997;8:922–928.

98. McCann SE, Moysich KB, Freudenheim JL, et al. Effects of soy intake on sex hormone metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:213–220.

99. Lu LJ, Cree M, Josyula S, et al. Increased urinay excretion of 2-hydroxyestrone but not 16alpha-hydroxysterone in premenopausal women during a soya diet containing isoflavones. Cancer Res 1999;60:1299–1305.

100. Nagata C, Takatsuka N, Inoua S, et al. Effect of soynilk consumption on serum estrogen concentrations in premenopausal Japanese women. J Natl Cancer Inst 1998;90:1830–1835.

101. Xu X, Duncan AM, Wangen KE, Kurzer MS. Soy consumption alters endogenous estrogen metabolism in postmenopausal women. J Natl Cancer Inst 2000;92:1879–1886.

102. Kilkkinen A, Virtamo J, Vartiainen E, et al. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study. Int J Cancer 2004;108:277–280.

103. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1999;90:814–823.

104. Key TJ. Serum estradiol and breast cancer risk. Endocr Relat Cancer 1999;6:175–180.

105. Thomas HV, Keeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997;8:922–928.

106. Key TJ, Chen J, Wang DY, et al. Sex hormones in women in rural China and in Britain. Br J Cancer 1990;62:631–636.

107. Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer 2002;94:1166–1174.

108. McCann SE, Moysich KB, Freudenheim JL, et al. Effects of soy intake on sex hormone metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:213–220.

109. Lu LJ, Cree M, Josyula S, et al. Increased urinary excretion of 2-hydroxyestrone but not 16alpha-hydroxysterone in premenopausal women during a soya diet containing isoflavones. Cancer Res 2000;60:1299–1305.

110. Maskarinec G, Pagano I, Lurie G, Kolonel LN. A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2006;15:732–739.

111. Wu AH, Stanczyk FZ, Hendrich S, et al. Metabolism of soymilk consumption on serum estrogen concentrations in premenopausal women. J Natl Cancer Inst 1998;90:1830–1835.

112. Xu X, Duncan AM, Wangen KE, Kurzer MS. Soy consumption alters endogenous estrogen metabolism in postmenopausal women. J Natl Cancer Inst 2000;92:1879–1886.

113. Martini MC, Dancisak BB, Haggans CJ, et al. Effects of soy intake on sex hormone metabolism in premenopausal women. Nutr Cancer 1999;34:133–139.

114. Maskarinec G, Williams AE, Inouye JS, et al. Effects of soy foods on ovarian function in premenopausal women. Br J Cancer 2000;82:1879–1886.

115. Petrek JA, Barton D. Estrogen deficiency: In search of symptom control and sexuality. J Natl Cancer Inst 2000;92:1026–1029.

116. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057–2071.

117. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999;340:1733–1739.

118. MacGregor CA, Canney PA, Patterson G, et al. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer 2005;41:708–714.

119. Nikander K, Kilikkinen A, Metsä-Helikki M, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 2003;101:1213–1220.

120. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy protein supplements on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 2002;20:1449–1455.

121. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 2000;18:1068–1074.
134. Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCCTG Trial N01CC1. J Clin Oncol 2006;24:2836–2841.

135. Jacobsen JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739–2745.

136. Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004;104:824–836.

137. Nedrow A, Miller J, Walker M, et al. Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med 2006;166:1453–1465.

138. Boyapati SM, Shu XO, Ruan ZX, et al. Soyfood intake and breast cancer survival: a follow-up of the Shanghai Breast Cancer Study. Cancer 2006;11:3828–3835.

139. Allred CD, Allred KE, Ju YH, et al. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovarioectomy of Sprague-Dawley rats. Carcinogenesis 2004;25:211–218.

140. Ju YH, Doerge DR, Allred KE, et al. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002;62:2474–2477.

141. Liu B, Edgerton S, Yang X, et al. Low-dose dietary phytoestrogens abrogates tamoxifen-associated mammary tumor prevention. Cancer Res 2005;65:879–886.

142. Luijten M, Thomsen AR, van den Berg JA, et al. Effects of soy-derived isoflavones and a high-fat diet on spontaneous mammary tumor development in TG:NR (MMTV-c-neu) mice. Nutr Cancer 2004;50:46–54.

143. Thomsen AR, Mortensen A, Brenholt VM, et al. Influence of Prevastin, an isoflavone-rich soy product, on mammary gland development and tumorigenesis in TG:NR (MMTV-c-neu) mice. Nutr Cancer 2005;52:176–188.

144. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 1998;58:3833–3838.

145. Lamartiniere CA, Moore J, Holland M, Barnes S. Neonatal genistein chemoprevents mammary cancer. Proc Soc Exp Biol Med 1995;206:120–123.

146. Lamartiniere CA, Moore JB, Brown NM, et al. Genistein suppresses mammary cancer in rats. Carcinogenesis 1995;16:2833–2840.

147. Gallo D, Giacomelli S, Cantello F, et al. Chemoprevention of DMBA-induced mammary cancer in rats by dietary soy. Breast Cancer Res Treat 2001;69:153–164.

148. Hilakivi-Clarke L, Onojafe I, Raygada M, et al. Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. Br J Cancer 1999;80:1682–1688.

149. Jin Z, MacDonald RS. Soy isoflavones increase latency of spontaneous mammary tumors in mice. J Nutr 2002;132:1860S–1863S.

150. Yan L, Li D, Yee JA. Dietary supplementation with isolated soy protein reduces metastases of mammary cancer cells in mice. Clin Exp Metastasis 2002;19:535–540.

151. De Assis S, Hilakivi-Clarke L. Timing of dietary estrogens and breast cancer risk. Ann N Y Acad Sci 2006;1089:14–35.

152. Lamartiniere CA. Timing of exposure and mammary cancer risk. J Mammary Gland Biol Neoplasia 2002;7:67–76.

153. Murrill WB, Brown NM, Zhang JX, et al. Prepubertal genistein exposure suppresses mammary cancer and delays gland differentiation in rats. Carcinogenesis 1996;17:1451–1457.

154. Fritz WA, Coward L, Wang J, Lamartiniere CA. Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat. Carcinogenesis 1999;19:2151–2158.

155. Hilakivi-Clarke L, Cho E, Onojafe I, et al. Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring. Oncol Rep 1999;6:1089–1095.

156. Allred CD, Ju YH, et al. Soy processing influences growth of estrogen-dependent breast cancer tumors. Carcinogenesis 2004;25:1649–1657.

157. Ju YH, Doerge DR, Allred KE, et al. Soy processing influences growth of estrogen-dependent breast cancer tumors. Carcinogenesis 2004;25:1649–1657.

158. Saarinen NM, Power K, Chen J, Thompson LU. Flaxseed attenuates the tumor growth stimulat- ing effect of soy protein in ovariectomized athymic mice with MCF-7 human breast cancer xenografts. Int J Cancer 2000;91:925–931.

159. Chen J, Hui E, Li T, Thompson LU. Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice. Clin Cancer Res 2004;10:7703–7711.

160. Chen J, Stavro PM, Thompson LU. Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutr Cancer 2002;43:187–192.

161. Chen J, Wang L, Thompson LU. Flaxseed and its components reduce metastasis after surgical excision of solid human breast tumor in nude mice. Cancer Lett 2006;234:168–175.

162. Dabrosin C, Chen J, Wang L, Thompson LU. Flaxseed inhibits metastasis and decreases extra-cellular vascular endothelial growth factor in human breast cancer xenografts. Cancer Lett 2002;180:37–45.

163. Wang L, Chen J, Thompson LU. The application to clinical practice. N Engl J Med 2006;98:1767–1776.